Block listing application

RNS Number : 7744S

Ergomed plc

27 June 2018

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Block listing application

London, UK - 27 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,800,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.

The New Ordinary Shares will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Share Incentive Plan. It is expected that admission will become effective on 2 July 2018.

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').

The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer	Tel: [phone]
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott / Ivar Milligan
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

ALSKMGZVGNGGRZM